| 引用本文: | 喻江龙,唐迅子,刘虹.IgA肾病新支持治疗策略研究进展[J].中国临床新医学,,():-. |
| Yu Jianglong,Tang Xunzi.IgA肾病新支持治疗策略研究进展[J].中国临床新医学,,():-. |
|
| 摘要: |
| IgA肾病（IgA nephropathy，IgAN）是全球最常见的原发性肾小球疾病，尤其在亚太地区该疾病负担沉重。该疾病预后异质性大——约30-40%的患者在20-30年内进展至终末期肾脏病（End Stage Renal Disease，ESRD），是构成我国尿毒症的重要病因。由于发病机制未明，IgAN的治疗面临挑战，传统治疗方式的局限性使得许多患者治疗需求未得以满足。我们重点分析了各类支持疗法在延缓IgAN进展中的疗效与安全性，并解读KDIGO 2025IgAN管理临床实践指南更新要点的临床意义。本综述旨在梳理IgAN支持治疗的证据体系，强调对IgAN患者进行个体化联合治疗的重要性，为临床诊疗提供参考。 |
| 关键词: IgA肾病 支持治疗 蛋白尿 |
| DOI： |
| 分类号: |
| 基金项目:国家自然科学(编号：82270752,82470741)；湖南省自然科学基金重点项目(编号：2025JJ30042)；2023年湖南省卫生健康高层次人才：领军人才（编号：20240304005） |
|
| Research Advances in Novel Supportive Treatment Strategies for IgA Nephropathy |
|
Yu Jianglong, Tang Xunzi
|
|
The Second Xiangya Hospital of Central South University
|
| Abstract: |
| Immunoglobulin A(IgA) nephropathy (IgAN), the most prevalent primary glomerular disease? worldwide, poses a particularly heavy disease burden in the Asia-Pacific region. The disease exhibits significant heterogeneity in prognosis—approximately 30–40% of patients progress to end-stage renal disease (ESRD)? within 20–30 years, making it a major contributor to the uremia? epidemic in China. The elusive pathogenesis of IgAN presents substantial therapeutic challenges, and the limitations of conventional treatments leave many patients" needs unmet. This review focuses on analyzing the efficacy and safety of various supportive therapies? in delaying the progression of IgAN and interprets the key updates in the clinical significance of the Kidney Disease: Improving Global Outcomes (KDIGO) 2025 Clinical Practice Guidelines for the Management of IgAN. It aims to synthesize the evidence framework for supportive care in IgAN, emphasizing the importance of personalized combination therapy? for affected individuals to inform clinical decision-making. |
| Key words: IgA nephropathy(IgAN) Epidemiology Proteinuria |
